drugset / Trial / NCT06423911
Study of Olverembatinib (HQP1351) in Patients With CP-CML
RandomizedParallel-groupOpen-labelTreatment
Summary
A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)
Timeline
- Start
- 2024-02-05
- Primary completion
- 2025-12
- Completion
- 2026-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bosutinib | Small molecule | — | — |
| Subject | Olverembatinib | Small molecule | — | — |